NasdaqGS:DYNBiotechs
How FDA Greenlight For DYNE-302 And Equity Raise At Dyne Therapeutics (DYN) Has Changed Its Investment Story
Dyne Therapeutics has received U.S. FDA clearance to begin a Phase 1 trial of DYNE-302 in facioscapulohumeral muscular dystrophy, while also reporting a second-quarter net loss of US$178.56 million and basic loss per share of US$1.08, both higher than a year earlier.
This clearance advances Dyne’s FORCE platform into a third clinical program targeting a rare muscle disease with no approved therapies, shortly after the company raised US$375.15 million in a follow-on equity offering.
We’ll now...